Recent news on Diclofenac

NSAIDs Counter Heart Benefits of HRT  -  25 May 2007
HeartZine,However the researchers found higher heart attack risk in those women who were also taking traditional NSAIDs such as ibuprofen, naproxen and diclofenac

Javelin Pharmaceuticals Signs Supply Pact with Baxter Healthcare  -  May 22, 2007
Genetic Engineering News (press release),Dylojectinjectable diclofenac sodium is under review for marketing approval in the UK for the treatment of acute moderate-to-severe pain.

Allegations of heart risk swirl around new Merck drug  -  May 8, 2007
Asbury Park Press,The problem, Nissen and other critics say, is that Merck's largest trial of Arcoxia compared it with an older NSAID, diclofenac. Though the trial found that

FDA rejects painkiller Arcoxia, Merck's Vioxx successor  -  Apr 30, 2007
The Northwest Florida Daily News,However, Arcoxia causes high blood pressure in more patients than diclofenac. Peter S. Kim, president of Merck Research Laboratories, told company

FDA rejects successor to Vioxx  -  Apr 28, 2007
Kansas City Star,However, Arcoxia causes high blood pressure in more patients than diclofenac. When the FDA advisory panel considered Arcoxia on April 12, David Graham,

Merck's Painkiller Arcoxia Is Rejected for US Sale (Update4)  -  Apr 27, 2007
BloombergDiclofenac and Arcoxia were equally effective in relieving pain, though Arcoxia was easier on the stomach. ``There is nothing special about this drug that

1221 and counting: More birds than ever face extinction  -  May 22, 2007
Surfbirds News...which to scavenge) and poisoning by the veterinary drug diclofenac – a factor behind rapid population declines in vultures across Asia in recent years.

Bradley Pharmaceuticals 2007 First Quarter Results  -  May 10, 2007
PR-Inside.com (Pressemitteilung),The increase in our net sales for the quarter ended March 31, 2007 was primarily led by the actinic keratosis product SOLARAZE(R) (diclofenac sodium- 3%)

Pharma Sector: Few Newsmakers Of The Week - Merck, Novartis ...  -  Apr 28, 2007
Trading Markets,The Medal Trial, which compared Arcoxia and standard treatment diclofenac, a non-steroidal anti-inflammatory drug, demonstrated that patients taking Arcoxia

Pharmos Corporation Reports 2007 First Quarter Results  -  May 11, 2007
PharmaLive.com (press release),2007 in preparing for a Phase 2a clinical trial with the Company's NanoEmulsion topical drug delivery vehicle with diclofenac for osteoarthritis pain.

There's a better way of disposing of your outdated drugs  -  May 9, 2007
McCook Daily Gazette,...lipid-regulating drugs phenazone and fenofibrate, analgesics such as ibuprofen and diclofenac, chemotherapy drugs, aspirin, caffeine and nicotine,

Nuvo announces first quarter 2007 financial results  -  May 1, 2007
Earthtimes.orgPennsaid(R) allows the diclofenac solution to be delivered to a specific site via the surface of the skin and thus limits complications associated with

No surprise as FDA turns down Merck & Co's Arcoxia  -  Apr 30, 2007
Pharma Times (subscription),The advisory panel had fiercely criticised the firm's choice of diclofenac as the comparator drug in its New Drug Application, arguing that it has higher

Unnecessary Scare About Common Painkillers Caused By FDA  -  Apr 29, 2007
Medical News Today (press release),The most commonly used NSAIDs are ibuprofen (Advil®), naproxen (Aleve®), and diclofenac (Voltaren®). There are more than a dozen others, including drugs

FDA Says No to Vioxx Successor  -  Apr 27, 2007
Washington Post,Wolfe noted that trial data presented by Merck on cardiovascular risks compared etoricoxib with the arthritis pain reliever diclofenac (brand name Voltaren)

Merck's Painkiller Arcoxia Is Rejected for US Sale (Update3)  -  Apr 27, 2007
Bloomberg...to cause increased blood pressure, fluid retention and congestive heart failure than another arthritis drug, diclofenac, according to the FDA's review.

Triad researcher: Drug regulators have botched safety issues  -  Apr 26, 2007
Bizjournals.com,High doses of other drugs, such as ibuprofen, sold under the brand name Advil, and diclofenac, sold as Voltaren, are associated with increased risk of heart

Low-Dose Aspirin Protection Against Cognitive Decline? Think Again  -  Apr 27, 2007
Psychiatric Times,...inconclusive or have shown no neuroprotective benefit for the NSAIDs rofecoxib, naproxen, nimesulide, and diclofenac, the ADAPT investigators noted.

Risk of myocardial infarction associated with selective COX-2 ...  -  Apr 26, 2007
HeartZine,Rofecoxib had a significantly higher risk of MI than naproxen (OR: 5.39; 95%: 2.08, 14.02) and valdecoxib had lower MI risk than diclofenac (OR: 0.14,

State testifies that Headley obtained the meds illegally  -  Apr 25, 2007
Nashville City Paper,But he had come into possession of thousands of each type of the pills – the pain medication hydrocodone, as well as cataflam, or diclofenac – without valid

Forget NSAIDs for Alzheimer's Prevention  -  Apr 25, 2007
Psychiatric Times,..."However, several subsequent trials have shown no benefit from treatment of Alzheimer's disease with rofecoxib, naproxen, nimesulide, or diclofenac," they

Risk of myocardial infarction associated with selective COX-2 ...  -  26 Apr 2007
HeartZine,Rofecoxib had a significantly higher risk of MI than naproxen (OR: 5.39; 95%: 2.08, 14.02) and valdecoxib had lower MI risk than diclofenac (OR: 0.14,

Triad researcher: Drug regulators have botched safety issues  -  26 Apr 2007
Charlotte Business Journal,High doses of other drugs, such as ibuprofen, sold under the brand name Advil, and diclofenac, sold as Voltaren, are associated with increased risk of heart

State testifies that Headley obtained the meds illegally  -  26 Apr 2007
Nashville City Paper,But he had come into possession of thousands of each type of the pills – the pain medication hydrocodone, as well as cataflam, or diclofenac – without valid

Forget NSAIDs for Alzheimer's Prevention  -  26 Apr 2007
MedPage Today,..."However, several subsequent trials have shown no benefit from treatment of Alzheimer's disease with rofecoxib, naproxen, nimesulide, or diclofenac," they

Vulture restaurant: diclofenac-free meat on platter  -  Apr 25, 2007
Down to Earth (subscription),If an animal falls ill, it’s treated with meloxicam, a newly introduced diclofenac substitute that does not harm vultures. If a cow dies before all traces

FDA whistle-blower shifts Arcoxia fight to Europe  -  Apr 15, 2007
USA TodayGraham says he would also like to see the FDA pull diclofenac off the market. Diclofenac and Arcoxia are both non-steroidal anti-inflammatory drugs,

Doctors: Arthritis drug Arcoxia risky too  -  Apr 9, 2007
USA TodayThe problem, Nissen and other critics say, is that Merck's largest trial of Arcoxia compared it with an older NSAID, diclofenac. Though the trial found that

Merck urges panel to back Vioxx successor  -  Apr 12, 2007
Scientific AmericanArcoxia, known generically as etoricoxib, offers an advantage because patients developed fewer ulcers compared with an older drug, diclofenac,

FDA Panel Frowns on Vioxx Successor  -  Apr 15, 2007
Wyoming News,Merck said the cardiovascular risk of Arcoxia was comparable to another older NSAID, diclofenac, based on the results of a study that enrolled nearly 35000

Judgment day for new Merck painkiller  -  Apr 10, 2007
CNNMoney.comThe FDA said tests showed that Arcoxia had "comparable" heart risk to diclofenac, a painkiller commonly prescribed in Europe that is a member of the same

FDA data cast doubt on pending Merck drug  -  Apr 10, 2007
Newark Star Ledger,A number of safety experts have said the available data show diclofenac itself carries an unacceptable risk of heart attacks, and are calling for Arcoxia to

FDA panel rejects Merck's Vioxx successor  -  Apr 13, 2007
Scientific AmericanGraham and others said Merck's decision to compare Arcoxia in a large safety study to an older medicine, diclofenac, was inappropriate because it is little

Vioxx successor's heart risks raising doubts  -  Apr 4, 2007
NorthJersey.com,..."They chose as a competitor the drug diclofenac, which has a worse risk of adverse cardiovascular events than Vioxx, so proving that Arcoxia is not worse

FDA panel rejects new Merck drug  -  Apr 13, 2007
NorthJersey.com,Merck said the cardiovascular risk of Arcoxia was comparable to that of another older NSAID, diclofenac, based on the results of a study that enrolled

FDA Panel Turns Down Merck Pill: Rejection of the Vioxx Successor ...  -  Apr 13, 2007
International News Service,Several panel members and speakers also questioned Merck's choice of diclofenac as a comparison drug in safety studies, because diclofenac itself has proved

Merck & Co in pain as FDA panel rips Arcoxia NDA to shreds  -  Apr 13, 2007
Pharma Times (subscription),The panel accepted the MEDAL data but were highly critical of the choice of comparator drug, arguing that diclofenac has higher heart risks than similar

FDA Panel Rejects Merck Pain Pill in 20-1 Vote  -  Apr 12, 2007
New York Times,So Merck switched to diclofenac, a pain medicine that is popular outside of the United States and is widely believed to be more dangerous to the heart than

FDA Scientist Blasts Proposed Pain Drug  -  Apr 12, 2007
CBS News,Merck said the cardiovascular risk of Arcoxia was comparable to another, older NSAID called diclofenac, based on the results of a study that enrolled nearly

Vioxx Successor Fails to Win Approval From FDA Panel  -  Apr 12, 2007
International News Service,Several panel members and speakers also questioned Merck's choice of diclofenac as a comparison drug in safety studies, because diclofenac itself has proven

Merck's Vioxx Successor Arcoxia Gets Knockout Punch From FDA ...  -  Apr 12, 2007
Trading Markets,The Medal Trial, which compared Arcoxia and standard treatment diclofenac, a non-steroidal anti-inflammatory drug demonstrated that patients taking Arcoxia

Arcoxia Rejected by Arthritis Advisory Committee  -  Apr 12, 2007
About - News & Issues,Merck claims Arcoxia was comparable to an older NSAID (nonsteroidal anti-inflammatory drug) diclofenac based on a study which involved 35000 patients.

What Was Merck Thinking?  -  Apr 13, 2007
Forbes,Merck decided to push forward with Arcoxia after the results of a big study comparing its cardiovascular risk with Voltaren, or diclofenac, from Novartis

Public Citizen: FDA Should Not Approve "Offspring of Vioxx" Painkiller  -  Apr 13, 2007
PharmaLive.com (press release),Further, with regards to serious gastrointestinal problems, there is no evidence of benefits of taking etoricoxib compared to diclofenac, a non-steroidal

FDA flags Vioxx successor  -  Apr 12, 2007
Pittsburgh Post Gazette,Merck said the cardiovascular risk of Arcoxia was comparable with another older NSAID, diclofenac, based on results of a study that enrolled nearly 35000

FDA Advisers Give Overwhelming Rejection to Etoricoxib (Arcoxia)  -  Apr 12, 2007
MedPage Today,Merck provided data that suggested etoricoxib had a cardiovascular safety profile that was comparable to diclofenac, an old NSAID that is rarely used in the

Arcoxia Not Recommended for Approval  -  Apr 17, 2007
Facts and Comparisons,...in other patient populations and data from the 34000-patient, long-term MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-Term) program.

FDA panel frowns on Vioxx successor  -  Apr 12, 2007
Herald News Daily,Diclofenac is widely used worldwide. In the US, however, it accounts for just 5 percent of the market for prescription NSAIDs.

Heart experts say Merck arthritis drug too risky  -  Apr 5, 2007
Scientific American...trial had a higher incidence of edema, elevated blood pressure and congestive heart failure than patients taking the standard treatment, diclofenac.

Heart risks in limelight as Merck's proposed Vioxx successor goes ...  -  Apr 11, 2007
Canada.com,The company said the cardiovascular risk of Arcoxia was comparable to another, older NSAID called diclofenac, based on the results of a study that enrolled

Merck Reports Risk of Its New Pain Pill  -  Apr 10, 2007
New York Times,Diclofenac, sold under names including Voltaren and Voltarol, is considered by some cardiologists to be among the most dangerous of standard arthritis

Vioxx successor faces trouble with FDA  -  Apr 11, 2007
NorthJersey.com,A study comparing Arcoxia with the generic medicine diclofenac found increased instances of high blood pressure, fluid retention and congestive heart

US FDA Staff Says Merck's Arcoxia Data Mixed  -  Apr 10, 2007
Reuters.uk,...attacks and other cardiovascular problems when compared with another analgesic, diclofenac, US reviewers said in an analysis made public on Tuesday.

Decision day approaches in the USA for Merck & Co's Arcoxia  -  Apr 11, 2007
Pharma Times (subscription),...cardiovascular events in patients who received Arcoxia was "comparable" to those who received the older non-steroidal anti-inflammatory drug diclofenac.

US FDA Staff Says Merck's Arcoxia Data Mixed  -  Apr 10, 2007
Reuters.uk,...who took pain reliever Arcoxia was similar to that with the older drug diclofenac, US regulatory reviewers said in documents made public on Tuesday.

FDA data cast doubt on pending Merck drug  -  Apr 10, 2007
Trenton Times,But the FDA said the clinical studies did not find any sta tistically significant difference in GI events compared with diclofenac.

Merck's new arthritis drug faces FDA approval hurdle  -  Apr 10, 2007
Newark Star Ledger,A number of safety experts have said that available data shows diclofenac carries a high and unacceptable risk of heart attacks, and called for Arcoxia to

Possible successor drug to Vioxx may raise blood pressure  -  Apr 10, 2007
Asbury Park Press,The drug was compared with the generic medicine diclofenac. Arcoxia was also found to be as effective as diclofenac at relieving pain from osteoarthritis

Pharmos' NanoEmulsion drug completes Phase I clinical trials  -  Apr 15, 2007
Globes,...(Nasdaq: PARS) announced last week that completed Phase I clinical trials of its NanoEmulsion drug delivery system for the topical application of Diclofenac

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional